NEXPLANON (etonogestrel)

Effective Date: 1/28/14
Date Developed: 1.28.14 by Robert Sterling, MD
Last Approval Date: 01.26.16, 01.24.17

NEXPLANON is a progestin implant indicated for use by women to prevent pregnancy.

Authorization: for contraception

Dosing: a single implant containing 68mg of the progestin etonogestrel inserted subdermally in the upper arm and replaced every three years

PRECAUTIONS: There are numerous precautions listed in the product literature, which should be consulted for details (e.g. ectopic pregnancy, PID/sepsis, perforation, device failure, bleeding, glucose intolerance)

DRUG INTERACTIONS: Drugs or herbal products that induce enzymes that metabolize progestins (e.g. CYP3A4) may decrease effectiveness (e.g. barbiturates, carbamazepine, oxcarbezepine, phenytoin, St. John’s wort). Variable changes in serum concentrations when used with protease inhibitors and other drugs used to treat HIV infection

REFERENCES


**Revision History:**

Date Reviewed/No Updates: 01.13.15 by C. Sanders, MD
Date Approved by P&T Committee: 01.27.15
Date Reviewed/No Updates: 01.26.16 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 01.26.16
Date Reviewed/No Updates: 01.24.17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 01.24.17

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>